Unknown

Dataset Information

0

Ubrogepant: First Approval.


ABSTRACT: Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (±?aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (±?aura) in adults.

SUBMITTER: Scott LJ 

PROVIDER: S-EPMC7062659 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7496299 | BioStudies
2020-01-01 | S-EPMC7214647 | BioStudies
2020-01-01 | S-EPMC7004213 | BioStudies
2019-01-01 | S-EPMC6865323 | BioStudies
2020-01-01 | S-EPMC7155006 | BioStudies
2020-01-01 | S-EPMC7158215 | BioStudies
2019-01-01 | S-EPMC6640487 | BioStudies
2018-01-01 | S-EPMC5935646 | BioStudies
1000-01-01 | S-EPMC6045522 | BioStudies
2020-01-01 | S-EPMC7214662 | BioStudies